Scandion Oncology A/S announces new date for publication of interim report January – March 2019

Report this content

Scandion Oncology A/S would like to make use of the full window for releasing the Q1 2019-report. The company therefore releases the Q1 2019-report on May 27, 2019. The previously reported reporting date was May 23, 2019.

For further information regarding Scandion Oncology A/S, please contact:

Nils Brünner, CEO

Phone: +45 26 14 47 08

E-mail: nb@scandiononcology.com 

www.scandiononcology.com

Scandion Oncology A/S is a biotechnology company founded in 2017 for the purpose of addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of cancer which contains drug resistant cell clones or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical animal studies, the company’s leading candidate drug, SCO-101, was found to significantly enhance the efficacy of certain standard cancer treatments when given in combination. In addition, SCO-101 restores chemotherapy sensitivity in in vitro grown resistant cancer cells. Scandion Oncology will in Q4 2019 initiate a clinical phase II study with SCO-101 in combination with chemotherapy. Scandion Oncology was listed on Spotlight, Sweden in November 2018.

Subscribe

Documents & Links